Jazz Pharmaceuticals strikes $1.32bn deal for Actio Biosciences to expand epilepsy franchise

Jazz Pharmaceuticals (JAZZ) said it would acquire privately held Actio Biosciences in a transaction valued at up to $1.32bn, adding a clinical-stage treatment for a severe rare epilepsy with no approved therapies to its neuroscience portfolio.

Under the terms of the deal, Actio shareholders will receive $820mn upfront and up to $500mn in additional payments tied to regulatory and commercial milestones. The transaction is expected to close in the fourth quarter of 2026, subject to customary conditions.

The agreement centers on ABS-1230, an experimental therapy being developed for KCNT1-related epilepsy, a rare genetic disorder that typically manifests in infancy and can cause dozens to hundreds of seizures per day, alongside significant developmental impairment. Jazz estimates the condition affects approximately 2,500 patients in the US. The company said ABS-1230 reduced seizure frequency in an early-stage pediatric study and is currently being evaluated in a trial intended to support a US regulatory filing.

The deal extends Jazz's existing epilepsy franchise beyond Epidiolex, the cannabidiol-based treatment approved in 2018 for certain rare seizure disorders. Gregory Renza, analyst at Truist, said the acquisition is consistent with Jazz's strategy of deepening its presence in rare diseases and bolstering its neurology pipeline.

Prior to closing, Actio will spin out a new privately held entity that will retain certain employees and programs focused on rare neurological diseases, including an experimental therapy for Charcot-Marie-Tooth disease, a hereditary peripheral nerve disorder. Jazz will hold a minority stake in the newly formed company.